Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
NCX 470 NDA submitted in China by Ocumension
August 10, 2026
What is the news ?
Ocumension has submitted an NDA to China’s National Medical Products Administration (NMPA) for NCX 470 to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension, using the same data package as recently submitted to the U.S. FDA.
What does it mean ?
NDAs for NCX 470 have now been submitted in two major territories, the United States and China, putting NCX 470 on the way to multiple approvals and launches over the next 12 to 24 months.